The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Angiogenesis Inhibitors Market Research Report 2024
Synopsis
Angiogenesis inhibitors are unique cancer-fighting agents because they block the growth of blood vessels that support tumor growth rather than blocking the growth of tumor cells themselves. Angiogenesis inhibitors interfere in several ways with various steps in blood vessel growth.
The global Angiogenesis Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Angiogenesis Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Angiogenesis Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Angiogenesis Inhibitors include Roche, Pfizer, Exelixis, Novarti, Takeda Pharmaceutical, Melinta Therapeutics, Cipla, Sun Pharmaceutical Industries, Bristol-Myers Squibb, Balaji Medical Services, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Angiogenesis Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiogenesis Inhibitors.
The Angiogenesis Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Angiogenesis Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angiogenesis Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Roche
Pfizer
Exelixis
Novarti
Takeda Pharmaceutical
Melinta Therapeutics
Cipla
Sun Pharmaceutical Industries
Bristol-Myers Squibb
Balaji Medical Services
Eli Lilly
Bayer
Sanofi
Merck & Co
Segment by Type
Oral
Injectable
Other
Segment by Application
Kidney Cancer
Lung Cancer
Breast Cancer
Colon Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Angiogenesis Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Angiogenesis Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Angiogenesis inhibitors are unique cancer-fighting agents because they block the growth of blood vessels that support tumor growth rather than blocking the growth of tumor cells themselves. Angiogenesis inhibitors interfere in several ways with various steps in blood vessel growth.
The global Angiogenesis Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Angiogenesis Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Angiogenesis Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Angiogenesis Inhibitors include Roche, Pfizer, Exelixis, Novarti, Takeda Pharmaceutical, Melinta Therapeutics, Cipla, Sun Pharmaceutical Industries, Bristol-Myers Squibb, Balaji Medical Services, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Angiogenesis Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiogenesis Inhibitors.
The Angiogenesis Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Angiogenesis Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angiogenesis Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Roche
Pfizer
Exelixis
Novarti
Takeda Pharmaceutical
Melinta Therapeutics
Cipla
Sun Pharmaceutical Industries
Bristol-Myers Squibb
Balaji Medical Services
Eli Lilly
Bayer
Sanofi
Merck & Co
Segment by Type
Oral
Injectable
Other
Segment by Application
Kidney Cancer
Lung Cancer
Breast Cancer
Colon Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Angiogenesis Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Angiogenesis Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Angiogenesis Inhibitors Market Overview
1.1 Product Definition
1.2 Angiogenesis Inhibitors by Type
1.2.1 Global Angiogenesis Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Injectable
1.2.4 Other
1.3 Angiogenesis Inhibitors by Application
1.3.1 Global Angiogenesis Inhibitors Market Value by Application (2024-2030)
1.3.2 Kidney Cancer
1.3.3 Lung Cancer
1.3.4 Breast Cancer
1.3.5 Colon Cancer
1.3.6 Other
1.4 Global Angiogenesis Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Angiogenesis Inhibitors Revenue 2019-2030
1.4.2 Global Angiogenesis Inhibitors Sales 2019-2030
1.4.3 Global Angiogenesis Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Angiogenesis Inhibitors Market Competition by Manufacturers
2.1 Global Angiogenesis Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Angiogenesis Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Angiogenesis Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Angiogenesis Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Angiogenesis Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Angiogenesis Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Angiogenesis Inhibitors, Date of Enter into This Industry
2.8 Global Angiogenesis Inhibitors Market Competitive Situation and Trends
2.8.1 Global Angiogenesis Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Angiogenesis Inhibitors Players Market Share by Revenue
2.8.3 Global Angiogenesis Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Angiogenesis Inhibitors Market Scenario by Region
3.1 Global Angiogenesis Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Angiogenesis Inhibitors Sales by Region: 2019-2030
3.2.1 Global Angiogenesis Inhibitors Sales by Region: 2019-2024
3.2.2 Global Angiogenesis Inhibitors Sales by Region: 2025-2030
3.3 Global Angiogenesis Inhibitors Revenue by Region: 2019-2030
3.3.1 Global Angiogenesis Inhibitors Revenue by Region: 2019-2024
3.3.2 Global Angiogenesis Inhibitors Revenue by Region: 2025-2030
3.4 North America Angiogenesis Inhibitors Market Facts & Figures by Country
3.4.1 North America Angiogenesis Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Angiogenesis Inhibitors Sales by Country (2019-2030)
3.4.3 North America Angiogenesis Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Angiogenesis Inhibitors Market Facts & Figures by Country
3.5.1 Europe Angiogenesis Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Angiogenesis Inhibitors Sales by Country (2019-2030)
3.5.3 Europe Angiogenesis Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Angiogenesis Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Angiogenesis Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Angiogenesis Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific Angiogenesis Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Angiogenesis Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Angiogenesis Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Angiogenesis Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Angiogenesis Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Angiogenesis Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Angiogenesis Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Angiogenesis Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Angiogenesis Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Angiogenesis Inhibitors Sales by Type (2019-2030)
4.1.1 Global Angiogenesis Inhibitors Sales by Type (2019-2024)
4.1.2 Global Angiogenesis Inhibitors Sales by Type (2025-2030)
4.1.3 Global Angiogenesis Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global Angiogenesis Inhibitors Revenue by Type (2019-2030)
4.2.1 Global Angiogenesis Inhibitors Revenue by Type (2019-2024)
4.2.2 Global Angiogenesis Inhibitors Revenue by Type (2025-2030)
4.2.3 Global Angiogenesis Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global Angiogenesis Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Angiogenesis Inhibitors Sales by Application (2019-2030)
5.1.1 Global Angiogenesis Inhibitors Sales by Application (2019-2024)
5.1.2 Global Angiogenesis Inhibitors Sales by Application (2025-2030)
5.1.3 Global Angiogenesis Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global Angiogenesis Inhibitors Revenue by Application (2019-2030)
5.2.1 Global Angiogenesis Inhibitors Revenue by Application (2019-2024)
5.2.2 Global Angiogenesis Inhibitors Revenue by Application (2025-2030)
5.2.3 Global Angiogenesis Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global Angiogenesis Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Angiogenesis Inhibitors Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Angiogenesis Inhibitors Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Exelixis
6.3.1 Exelixis Company Information
6.3.2 Exelixis Description and Business Overview
6.3.3 Exelixis Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Exelixis Angiogenesis Inhibitors Product Portfolio
6.3.5 Exelixis Recent Developments/Updates
6.4 Novarti
6.4.1 Novarti Company Information
6.4.2 Novarti Description and Business Overview
6.4.3 Novarti Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novarti Angiogenesis Inhibitors Product Portfolio
6.4.5 Novarti Recent Developments/Updates
6.5 Takeda Pharmaceutical
6.5.1 Takeda Pharmaceutical Company Information
6.5.2 Takeda Pharmaceutical Description and Business Overview
6.5.3 Takeda Pharmaceutical Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Takeda Pharmaceutical Angiogenesis Inhibitors Product Portfolio
6.5.5 Takeda Pharmaceutical Recent Developments/Updates
6.6 Melinta Therapeutics
6.6.1 Melinta Therapeutics Company Information
6.6.2 Melinta Therapeutics Description and Business Overview
6.6.3 Melinta Therapeutics Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Melinta Therapeutics Angiogenesis Inhibitors Product Portfolio
6.6.5 Melinta Therapeutics Recent Developments/Updates
6.7 Cipla
6.7.1 Cipla Company Information
6.7.2 Cipla Description and Business Overview
6.7.3 Cipla Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Cipla Angiogenesis Inhibitors Product Portfolio
6.7.5 Cipla Recent Developments/Updates
6.8 Sun Pharmaceutical Industries
6.8.1 Sun Pharmaceutical Industries Company Information
6.8.2 Sun Pharmaceutical Industries Description and Business Overview
6.8.3 Sun Pharmaceutical Industries Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sun Pharmaceutical Industries Angiogenesis Inhibitors Product Portfolio
6.8.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.9 Bristol-Myers Squibb
6.9.1 Bristol-Myers Squibb Company Information
6.9.2 Bristol-Myers Squibb Description and Business Overview
6.9.3 Bristol-Myers Squibb Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bristol-Myers Squibb Angiogenesis Inhibitors Product Portfolio
6.9.5 Bristol-Myers Squibb Recent Developments/Updates
6.10 Balaji Medical Services
6.10.1 Balaji Medical Services Company Information
6.10.2 Balaji Medical Services Description and Business Overview
6.10.3 Balaji Medical Services Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Balaji Medical Services Angiogenesis Inhibitors Product Portfolio
6.10.5 Balaji Medical Services Recent Developments/Updates
6.11 Eli Lilly
6.11.1 Eli Lilly Company Information
6.11.2 Eli Lilly Description and Business Overview
6.11.3 Eli Lilly Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Eli Lilly Angiogenesis Inhibitors Product Portfolio
6.11.5 Eli Lilly Recent Developments/Updates
6.12 Bayer
6.12.1 Bayer Company Information
6.12.2 Bayer Description and Business Overview
6.12.3 Bayer Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Bayer Angiogenesis Inhibitors Product Portfolio
6.12.5 Bayer Recent Developments/Updates
6.13 Sanofi
6.13.1 Sanofi Company Information
6.13.2 Sanofi Description and Business Overview
6.13.3 Sanofi Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Sanofi Angiogenesis Inhibitors Product Portfolio
6.13.5 Sanofi Recent Developments/Updates
6.14 Merck & Co
6.14.1 Merck & Co Company Information
6.14.2 Merck & Co Description and Business Overview
6.14.3 Merck & Co Angiogenesis Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Merck & Co Angiogenesis Inhibitors Product Portfolio
6.14.5 Merck & Co Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Angiogenesis Inhibitors Industry Chain Analysis
7.2 Angiogenesis Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Angiogenesis Inhibitors Production Mode & Process
7.4 Angiogenesis Inhibitors Sales and Marketing
7.4.1 Angiogenesis Inhibitors Sales Channels
7.4.2 Angiogenesis Inhibitors Distributors
7.5 Angiogenesis Inhibitors Customers
8 Angiogenesis Inhibitors Market Dynamics
8.1 Angiogenesis Inhibitors Industry Trends
8.2 Angiogenesis Inhibitors Market Drivers
8.3 Angiogenesis Inhibitors Market Challenges
8.4 Angiogenesis Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Angiogenesis Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Angiogenesis Inhibitors Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Angiogenesis Inhibitors Market Competitive Situation by Manufacturers in 2023
Table 4. Global Angiogenesis Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Angiogenesis Inhibitors Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Angiogenesis Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Angiogenesis Inhibitors Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Angiogenesis Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Angiogenesis Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Angiogenesis Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Angiogenesis Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Angiogenesis Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Angiogenesis Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiogenesis Inhibitors as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Angiogenesis Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Angiogenesis Inhibitors Sales by Region (2019-2024) & (K Units)
Table 18. Global Angiogenesis Inhibitors Sales Market Share by Region (2019-2024)
Table 19. Global Angiogenesis Inhibitors Sales by Region (2025-2030) & (K Units)
Table 20. Global Angiogenesis Inhibitors Sales Market Share by Region (2025-2030)
Table 21. Global Angiogenesis Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Angiogenesis Inhibitors Revenue Market Share by Region (2019-2024)
Table 23. Global Angiogenesis Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Angiogenesis Inhibitors Revenue Market Share by Region (2025-2030)
Table 25. North America Angiogenesis Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)
Table 27. North America Angiogenesis Inhibitors Sales by Country (2025-2030) & (K Units)
Table 28. North America Angiogenesis Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Angiogenesis Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Angiogenesis Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)
Table 32. Europe Angiogenesis Inhibitors Sales by Country (2025-2030) & (K Units)
Table 33. Europe Angiogenesis Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Angiogenesis Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Angiogenesis Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Angiogenesis Inhibitors Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Angiogenesis Inhibitors Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Angiogenesis Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Angiogenesis Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Angiogenesis Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Angiogenesis Inhibitors Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Angiogenesis Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Angiogenesis Inhibitors Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Angiogenesis Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Angiogenesis Inhibitors Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Angiogenesis Inhibitors Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Angiogenesis Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Angiogenesis Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Angiogenesis Inhibitors Sales (K Units) by Type (2019-2024)
Table 51. Global Angiogenesis Inhibitors Sales (K Units) by Type (2025-2030)
Table 52. Global Angiogenesis Inhibitors Sales Market Share by Type (2019-2024)
Table 53. Global Angiogenesis Inhibitors Sales Market Share by Type (2025-2030)
Table 54. Global Angiogenesis Inhibitors Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Angiogenesis Inhibitors Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Angiogenesis Inhibitors Revenue Market Share by Type (2019-2024)
Table 57. Global Angiogenesis Inhibitors Revenue Market Share by Type (2025-2030)
Table 58. Global Angiogenesis Inhibitors Price (US$/Unit) by Type (2019-2024)
Table 59. Global Angiogenesis Inhibitors Price (US$/Unit) by Type (2025-2030)
Table 60. Global Angiogenesis Inhibitors Sales (K Units) by Application (2019-2024)
Table 61. Global Angiogenesis Inhibitors Sales (K Units) by Application (2025-2030)
Table 62. Global Angiogenesis Inhibitors Sales Market Share by Application (2019-2024)
Table 63. Global Angiogenesis Inhibitors Sales Market Share by Application (2025-2030)
Table 64. Global Angiogenesis Inhibitors Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Angiogenesis Inhibitors Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Angiogenesis Inhibitors Revenue Market Share by Application (2019-2024)
Table 67. Global Angiogenesis Inhibitors Revenue Market Share by Application (2025-2030)
Table 68. Global Angiogenesis Inhibitors Price (US$/Unit) by Application (2019-2024)
Table 69. Global Angiogenesis Inhibitors Price (US$/Unit) by Application (2025-2030)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Roche Angiogenesis Inhibitors Product
Table 74. Roche Recent Developments/Updates
Table 75. Pfizer Company Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Pfizer Angiogenesis Inhibitors Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Exelixis Company Information
Table 81. Exelixis Description and Business Overview
Table 82. Exelixis Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Exelixis Angiogenesis Inhibitors Product
Table 84. Exelixis Recent Developments/Updates
Table 85. Novarti Company Information
Table 86. Novarti Description and Business Overview
Table 87. Novarti Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novarti Angiogenesis Inhibitors Product
Table 89. Novarti Recent Developments/Updates
Table 90. Takeda Pharmaceutical Company Information
Table 91. Takeda Pharmaceutical Description and Business Overview
Table 92. Takeda Pharmaceutical Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Takeda Pharmaceutical Angiogenesis Inhibitors Product
Table 94. Takeda Pharmaceutical Recent Developments/Updates
Table 95. Melinta Therapeutics Company Information
Table 96. Melinta Therapeutics Description and Business Overview
Table 97. Melinta Therapeutics Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Melinta Therapeutics Angiogenesis Inhibitors Product
Table 99. Melinta Therapeutics Recent Developments/Updates
Table 100. Cipla Company Information
Table 101. Cipla Description and Business Overview
Table 102. Cipla Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Cipla Angiogenesis Inhibitors Product
Table 104. Cipla Recent Developments/Updates
Table 105. Sun Pharmaceutical Industries Company Information
Table 106. Sun Pharmaceutical Industries Description and Business Overview
Table 107. Sun Pharmaceutical Industries Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Sun Pharmaceutical Industries Angiogenesis Inhibitors Product
Table 109. Sun Pharmaceutical Industries Recent Developments/Updates
Table 110. Bristol-Myers Squibb Company Information
Table 111. Bristol-Myers Squibb Description and Business Overview
Table 112. Bristol-Myers Squibb Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Bristol-Myers Squibb Angiogenesis Inhibitors Product
Table 114. Bristol-Myers Squibb Recent Developments/Updates
Table 115. Balaji Medical Services Company Information
Table 116. Balaji Medical Services Description and Business Overview
Table 117. Balaji Medical Services Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Balaji Medical Services Angiogenesis Inhibitors Product
Table 119. Balaji Medical Services Recent Developments/Updates
Table 120. Eli Lilly Company Information
Table 121. Eli Lilly Description and Business Overview
Table 122. Eli Lilly Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Eli Lilly Angiogenesis Inhibitors Product
Table 124. Eli Lilly Recent Developments/Updates
Table 125. Bayer Company Information
Table 126. Bayer Description and Business Overview
Table 127. Bayer Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Bayer Angiogenesis Inhibitors Product
Table 129. Bayer Recent Developments/Updates
Table 130. Sanofi Company Information
Table 131. Sanofi Description and Business Overview
Table 132. Sanofi Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Sanofi Angiogenesis Inhibitors Product
Table 134. Sanofi Recent Developments/Updates
Table 135. Merck & Co Company Information
Table 136. Merck & Co Description and Business Overview
Table 137. Merck & Co Angiogenesis Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Merck & Co Angiogenesis Inhibitors Product
Table 139. Merck & Co Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Angiogenesis Inhibitors Distributors List
Table 143. Angiogenesis Inhibitors Customers List
Table 144. Angiogenesis Inhibitors Market Trends
Table 145. Angiogenesis Inhibitors Market Drivers
Table 146. Angiogenesis Inhibitors Market Challenges
Table 147. Angiogenesis Inhibitors Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Angiogenesis Inhibitors
Figure 2. Global Angiogenesis Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Angiogenesis Inhibitors Market Share by Type: 2023 & 2030
Figure 4. Oral Product Picture
Figure 5. Injectable Product Picture
Figure 6. Other Product Picture
Figure 7. Global Angiogenesis Inhibitors Market Value by Application (2024-2030) & (US$ Million)
Figure 8. Global Angiogenesis Inhibitors Market Share by Application: 2023 & 2030
Figure 9. Kidney Cancer
Figure 10. Lung Cancer
Figure 11. Breast Cancer
Figure 12. Colon Cancer
Figure 13. Other
Figure 14. Global Angiogenesis Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Angiogenesis Inhibitors Market Size (2019-2030) & (US$ Million)
Figure 16. Global Angiogenesis Inhibitors Sales (2019-2030) & (K Units)
Figure 17. Global Angiogenesis Inhibitors Average Price (US$/Unit) & (2019-2030)
Figure 18. Angiogenesis Inhibitors Report Years Considered
Figure 19. Angiogenesis Inhibitors Sales Share by Manufacturers in 2023
Figure 20. Global Angiogenesis Inhibitors Revenue Share by Manufacturers in 2023
Figure 21. Global 5 and 10 Largest Angiogenesis Inhibitors Players: Market Share by Revenue in Angiogenesis Inhibitors in 2023
Figure 22. Angiogenesis Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 23. Global Angiogenesis Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Angiogenesis Inhibitors Sales Market Share by Country (2019-2030)
Figure 25. North America Angiogenesis Inhibitors Revenue Market Share by Country (2019-2030)
Figure 26. United States Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Angiogenesis Inhibitors Sales Market Share by Country (2019-2030)
Figure 29. Europe Angiogenesis Inhibitors Revenue Market Share by Country (2019-2030)
Figure 30. Germany Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Russia Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Angiogenesis Inhibitors Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Angiogenesis Inhibitors Revenue Market Share by Region (2019-2030)
Figure 37. China Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. China Taiwan Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Angiogenesis Inhibitors Sales Market Share by Country (2019-2030)
Figure 45. Mexico Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Colombia Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East and Africa Angiogenesis Inhibitors Sales Market Share by Country (2019-2030)
Figure 50. Middle East and Africa Angiogenesis Inhibitors Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Angiogenesis Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Angiogenesis Inhibitors by Type (2019-2030)
Figure 55. Global Revenue Market Share of Angiogenesis Inhibitors by Type (2019-2030)
Figure 56. Global Angiogenesis Inhibitors Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Angiogenesis Inhibitors by Application (2019-2030)
Figure 58. Global Revenue Market Share of Angiogenesis Inhibitors by Application (2019-2030)
Figure 59. Global Angiogenesis Inhibitors Price (US$/Unit) by Application (2019-2030)
Figure 60. Angiogenesis Inhibitors Value Chain
Figure 61. Angiogenesis Inhibitors Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
